Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)“Unprecedented” PFS Benefit with Selinexor in p53 Wild-Type Endometrial Cancer

The discovery sheds new light on its potential role in the management of a disease that affects roughly half of all advanced or recurrent endometrial cancer patients.

Maintenance therapy with selinexor, an oral exportin 1 (XPO1) inhibitor, has been found to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer. A subset analysis of the phase 3 SIENDO trial, presented at the July 2023 session of ASCO, shows a dramatic improvement in median PFS in a specific group of patients.

Key Points:

  • SIENDO trial evaluated selinexor vs. placebo in 263 patients with advanced or recurrent endometrial cancer in remission.
  • Median PFS was 27.4 months with selinexor vs. 5.2 months with placebo in wild-type TP53 patients, at a median follow-up of 25.3 months.
  • Most common adverse events include nausea, vomiting, diarrhea; grade 3 or higher included neutropenia, nausea, thrombocytopenia.
  • Selinexor has FDA approval for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma but is investigational for endometrial cancer.

Additional Points:

  • The new data is described as “unprecedented” and provides a plausible biological hypothesis for this subset benefit.
  • A new phase 3 trial (XPORT-EC-042) is underway, focusing on p53 wild-type advanced or recurrent endometrial cancer with 220 participants targeted.


  • The significant PFS benefit with selinexor opens a promising avenue in treating wild-type TP53 endometrial cancer, with ongoing research to confirm and explore these remarkable findings.

OBGYN Latest Posts

“The PFS benefit for selinexor in the p53 wild-type population is unprecedented. There’s a plausible biological hypothesis for this subset benefit.”

Gini Fleming, MD
Discussant for the ASCO Session
Medical Director of Gynecologic Oncology
University of Chicago Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form